IDEAYA Biosciences Inc

In a Stage 3 distribution phase with weakening upside momentum and a failed recovery into declining EMAs, price is forming lower highs and tracking below the 9 and 21 EMA. Overbought context and elevated stage transition risk support a medium-term bearish bias, and short-term timing favors immediate downside participation on rallies into the EMA resistance zone. We engage via Sell Now at EMA tests within the downtrending structure.

• ↑Initiation of Phase 1/2 IDE892 study targets MTAP-deleted pancreatic and lung cancers.
• ↑$1.1B in cash and marketable securities as of Sep 30, 2025 funds operations into 2030.
• ↓Negative earnings yield and weak profitability indicate ongoing losses.